Venom Immunotherapy Does Not Affect Survival of Patients with Malignant Tumor in Poland.

Autor: Chełmińska M; Department of Allergology, Medical University of Gdańsk, 80-952 Gdańsk, Poland., Specjalski K; Department of Allergology, Medical University of Gdańsk, 80-952 Gdańsk, Poland., Jassem E; Department of Pneumonology, Medical University of Gdańsk, 80-952 Gdańsk, Poland., Polańska J; Department of Data Science and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland., Kita K; Department of Allergology, Medical University of Gdańsk, 80-952 Gdańsk, Poland., Górska L; Department of Allergology, Medical University of Gdańsk, 80-952 Gdańsk, Poland., Didkowska J; National Institute of Oncology, 00-001 Warsaw, Poland., Wojciechowska U; National Institute of Oncology, 00-001 Warsaw, Poland., Nittner-Marszalska M; Department of Internal Diseases, Pneumonology and Allergology, Medical University of Wroclaw, 50-368 Wroclaw, Poland., Kuna P; Department of Internal Diseases, Asthma and Allergy, Medical University of Łódź, 90-419 Łódż, Poland., Kupczyk M; Department of Internal Diseases, Asthma and Allergy, Medical University of Łódź, 90-419 Łódż, Poland., Kruszewski J; Department of Infectious Diseases and Allergology, Military Institute of Medicine, 04-141 Warsaw, Poland., Zakrzewski A; Department of Infectious Diseases and Allergology, Military Institute of Medicine, 04-141 Warsaw, Poland., Czarnobilska E; Centre of Clinical and Environmental Allergology, Jagiellonian University, 31-503 Cracow, Poland., Stobiecki M; Centre of Clinical and Environmental Allergology, Jagiellonian University, 31-503 Cracow, Poland., Krenke R; Department of Internal Diseases, Pneumonology and Allergology, Medical University of Warsaw, 02-097 Warsaw, Poland., Dąbrowski A; Department of Internal Diseases, Pneumonology and Allergology, Medical University of Warsaw, 02-097 Warsaw, Poland., Kwaśniewski A; Hospital CDT Medicus Sp. z o. o., 59-300 Lubin, Poland., Jarząb J; Clinical Department of Internal Medicine, Dermatology and Allergology, Medical University of Silesia, 40-055 Zabrze, Poland., Bożek A; Clinical Department of Internal Medicine, Dermatology and Allergology, Medical University of Silesia, 40-055 Zabrze, Poland., Bodzenta-Łukaszyk A; Department of Allergology and Internal Diseases, University Hospital, 15-089 Białystok, Poland., Łukaszyk M; I Department of Pulmonary Diseases and Tuberculosis, Medical University of Białystok, 15-089 Białystok, Poland., Kowalski M; Department of Immunology, Reumatology and Allergy, Medical University of Łódź, 92-213 Łódź, Poland., Smorawska-Sabanty E; Department of Immunology, Reumatology and Allergy, Medical University of Łódź, 92-213 Łódź, Poland., Fal A; Department of Allergology, Pulmonary Diseases and Internal Medicine, MSWiA Central Clinical Hospital, 02-507 Warsaw, Poland., Przybyłowska K; Department of Allergology, Pulmonary Diseases and Internal Medicine, MSWiA Central Clinical Hospital, 02-507 Warsaw, Poland., Bartuzi Z; Department of Allergology, Clinical Immunology and Internal Diseases, Jan Biziel University Hospital, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland., Pałgan K; Department of Allergology, Clinical Immunology and Internal Diseases, Jan Biziel University Hospital, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland., Niedoszytko M; Department of Allergology, Medical University of Gdańsk, 80-952 Gdańsk, Poland.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 May 28; Vol. 13 (11). Date of Electronic Publication: 2024 May 28.
DOI: 10.3390/jcm13113152
Abstrakt: Background: Allergen immunotherapy (AIT) is a well-established and efficient method of causative treatment for allergic rhinitis, asthma and insect venom allergy. Traditionally, a recent history of malignant neoplasm is regarded as a contraindication to AIT due to concerns that AIT might stimulate tumor growth. However, there are no data confirming that the silencing of the Th2 response affects prognosis in cancer. Objectives: The aim of this study was to investigate frequency of malignant tumors in patients undergoing AIT and the association between AIT and cancer-related mortality. Patients and Methods: A group of 2577 patients with insect venom allergy undergoing AIT in 10 Polish allergology centers was screened in the Polish National Cancer Registry. Data on cancer type, diagnosis time and patients' survival were collected and compared with the general population. Results: In the study group, 86 cases of malignancies were found in 85 patients (3.3% of the group). The most common were breast (19 cases), lung (9 cases), skin (8 cases), colon and prostate cancers (5 cases each). There were 21 cases diagnosed before AIT, 38 during and 27 after completing AIT. Laplace's crude incidence rate was 159.5/100,000/year (general population rate: 260/100,000/year). During follow-up, 13 deaths related to cancer were revealed (15% of patients with cancer). Laplace's cancer mortality rate was 37.3/100,000/year (general population rate: 136.8/100,000/year). Conclusions: Malignancy was found in patients undergoing immunotherapy less often than in the general population. Patients with cancer diagnosed during or after AIT did not show a lower survival rate, which suggests that AIT does not affect the prognosis.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje